Tonix Pharmaceuticals Unveils Promising Preclinical Data for Two Immuno-Oncology Candidates at AACR 2026
Event summary
- Tonix presented preclinical data on TNX-1700 and TNX-4700 at AACR Annual Meeting 2026, held April 17-22 in San Diego.
- TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and attenuated tumor progression in preclinical models.
- TNX-4700 demonstrated potent, high-affinity binding and functional antagonism of BTLA in vitro.
- TNX-1700 exhibited dose-independent, linear pharmacokinetics in animals.
The big picture
Tonix's presentation at AACR highlights its expanding focus on immuno-oncology, complementing its existing CNS and immunology portfolio. The company is positioning itself as a player in the competitive cancer immunotherapy space by targeting novel mechanisms like BTLA inhibition and TFF2 modulation. Success in these programs could diversify Tonix's revenue streams beyond its current commercial products.
What we're watching
- Clinical Translation
- Whether TNX-1700's ability to reverse aging-associated gastric inflammation will translate into clinical efficacy in human trials.
- Combination Therapy
- The pace at which Tonix advances TNX-1700 and TNX-4700 into combination therapy trials with PD-1 inhibitors.
- Regulatory Pathway
- How quickly Tonix can progress from preclinical to IND stage for these immuno-oncology candidates.
Related topics